3,099 Shares in Astrazeneca Plc $AZN Purchased by South Shore Capital Advisors

South Shore Capital Advisors acquired a new stake in Astrazeneca Plc (NYSE:AZN) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 3,099 shares of the company’s stock, valued at approximately $285,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in AZN. Brighton Jones LLC lifted its holdings in shares of Astrazeneca by 93.2% during the 4th quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock worth $379,000 after acquiring an additional 2,789 shares during the period. AQR Capital Management LLC raised its position in shares of Astrazeneca by 45.3% in the first quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock valued at $2,756,000 after purchasing an additional 11,690 shares during the period. Rhumbline Advisers grew its stake in Astrazeneca by 3.3% during the second quarter. Rhumbline Advisers now owns 29,064 shares of the company’s stock valued at $2,031,000 after acquiring an additional 922 shares in the last quarter. Norges Bank purchased a new stake in shares of Astrazeneca in the 2nd quarter valued at $4,219,000. Finally, Amundi raised its holdings in Astrazeneca by 54.4% in the 2nd quarter. Amundi now owns 10,274 shares of the company’s stock worth $731,000 after purchasing an additional 3,618 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. HSBC reissued a “buy” rating and issued a $108.00 price objective on shares of Astrazeneca in a report on Wednesday, December 10th. TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Astrazeneca in a research note on Friday, February 6th. Wall Street Zen cut Astrazeneca from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Citigroup began coverage on Astrazeneca in a research note on Tuesday, January 27th. They issued a “buy” rating on the stock. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Astrazeneca currently has an average rating of “Moderate Buy” and an average price target of $95.75.

Astrazeneca Price Performance

Shares of AZN opened at $202.85 on Tuesday. The company has a market capitalization of $314.60 billion, a PE ratio of 30.97, a P/E/G ratio of 1.53 and a beta of 0.35. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 0.51. Astrazeneca Plc has a 1 year low of $122.48 and a 1 year high of $212.71.

Astrazeneca Dividend Announcement

The company also recently declared a dividend, which was paid on Monday, March 23rd. Shareholders of record on Friday, February 20th were given a dividend of $1.595 per share. The ex-dividend date of this dividend was Friday, February 20th. This represents a yield of 156.0%. Astrazeneca’s dividend payout ratio is 66.26%.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.